CA 15-3, mucin-like carcinoma-associated antigen and tissue polypeptide-specific antigen: correlation to disease state and prognosis in breast cancer patients. 1995

A D Cohen, and J Gopas, and G Karplus, and Y Cohen
Department of Oncology, Soroka Medical Center, Beer Sheva, Israel.

Serum testing for the tumor markers CA 15-3 and mucin-like carcinoma-associated antigen (MCA) was performed in 144 patients with breast cancer. Of those patients, 127 were also tested for a third tumor marker, tissue polypeptide-specific antigen (TPS). At the time of testing, 73 patients (51%) were without evidence of disease and 71 patients (49%) had active disease. Mean follow-up time was 16 months. Positivity rates were: 29.8% for CA 15-3, 47.2% for MCA, and 58.3% for TPS. Mean value for patients with no evidence of disease as compared to patients with active disease was 21 U/ml and 117 U/ml for CA 15-3 (P = 0.001), 10.2 kU/l and 22.6 kU/l for MCA (P = 0.001), and 148 U/l and 310 U/l for TPS (P = 0.02). Two year actuarial survival, according to values below and above an established cutoff for CA 15-3 were 80% and 31% (P < 0.001), 75% and 45% for MCA (P < 0.01), and 82% and 50% for TPS (P < 0.01). We conclude that CA 15-3, MCA and TPS values reflect disease state and prognosis in breast cancer patients.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers

Related Publications

A D Cohen, and J Gopas, and G Karplus, and Y Cohen
August 1989, Klinische Wochenschrift,
A D Cohen, and J Gopas, and G Karplus, and Y Cohen
January 1991, European journal of cancer (Oxford, England : 1990),
A D Cohen, and J Gopas, and G Karplus, and Y Cohen
June 2000, East African medical journal,
A D Cohen, and J Gopas, and G Karplus, and Y Cohen
January 1990, The International journal of biological markers,
A D Cohen, and J Gopas, and G Karplus, and Y Cohen
January 1993, The International journal of biological markers,
A D Cohen, and J Gopas, and G Karplus, and Y Cohen
November 1998, Clinical chemistry and laboratory medicine,
A D Cohen, and J Gopas, and G Karplus, and Y Cohen
July 2001, Breast cancer research and treatment,
A D Cohen, and J Gopas, and G Karplus, and Y Cohen
January 1994, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Copied contents to your clipboard!